The role of cognitive and emotional risk factors in decision-making
- Conditions
- Adjustment disordersF31.3F31.4Bipolar affective disorder, current episode severe depression without psychotic symptomsF32Depressive episodeBipolar affective disorder, current episode mild or moderate depressionF33F43.2Recurrent depressive disorder
- Registration Number
- DRKS00015610
- Lead Sponsor
- niversitätsklinikum der RWTH Aachen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
General inclusion criteria:
- Subject is 18 to 60 years of age on the day of signing informed consent.
- Subject agrees to participate by providing written informed consent
- Subject is able to obtain full insight into the objectives of the clinical trial and is fully contractually capable as assessed by an independent psychiatrist.
- For patients: voluntary treatment in the Department for Psychiatry, Psychotherapy and Psychosomatics.
Special inclusion criteria:
Group 1
- Suicidal behavior (suicide ideas, realized or interrupted suicide attempts) within the last 6 months
- Subject meets ICD-10 criteria for single depressive episode (F32.x), bipolar depression (F31.x), recurrent depression (F33.x) or adjustment disorder with depressive reaction (F43.2).
- Absence of acute suicidality and stabile psychopathological state.
- Persistence of depressive symptoms (BDI = 14).
Group 2
- Lifetime absence of suicidal behavior (suicide ideas, realized or interrupted suicide attempts)
- Subject meets ICD-10 criteria for single depressive episode (F32.x), bipolar depression (F31.x), recurrent depression (F33.x) or adjustment disorder with depressive reaction (F43.2).
- Absence of acute suicidality and stabile psychopathological state.
- Persistence of depressive symptoms (BDI = 14).
Group 3
- Healthy volunteers without a history of mental diseases or suicidality
- Any comorbidity including following diagnostic categories: Organic, including symptomatic, mental disorders (F00-F09), Schizophrenia, schizotypal and delusional disorders (F20-F29), Mental retardation (F70-F79), Disorders of psychological development (F80-89).
- Subject has an unstable, severe medical disorder.
- Subject is hospitalized or treated coercively by order of the responsible local authorities.
- Subject (in the investigator's and - if necessary - an independent psychiatrist’s judgment) poses a serious suicidal or homicidal risk at the screening visit
- Subject has a clinically significant abnormality in the neurological assessments at screen or base
- subject is in a dependent position toward the investigators.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The current study aims to test previously suicidal, depressed patients compared to depressed patients without suicidality and healthy controls with regard to following primary outcome parameters:<br>Decision-making task (DOSE): loss aversion und risk aversion <br>Emotional stroop task (EST): Interference effect<br>Stop-Signal-Response-Task (SSRT): Inhibition effect <br>Childhood Trauma Questionnaire (CTQ): summarized score and subscores for physical, mental and sexual traumatic experience <br>
- Secondary Outcome Measures
Name Time Method The secondary outcome parameters will be assessed using the following questionnaires and examinations:<br>-Becks Depressions Inventory-II (BDI-II; Self rating) und Hamilton Depression Scale (HAMD) (external rating)<br>-Suicide Severity Rating Scale (C-SSRS), German Capability for Suicide Questionnaire (GCSQ), Interpersonal Needs Questionnaire (INQ) (assessment of suicidality) <br>-Beck Hopelessness Scale (assessment of hopelessness)<br>-Temperament and Character Inventory (TCI) (assessment of personality attributes)<br>- Trail Making Task – TMT(A) und TMT(B) (cognitive flexibility)<br>- Barratt Impulsiveness Scale (BIS-11) (Impulsiveness)<br>-Cognitive Fusion Questionnaire (CFQ-D) und Metacognitions Questionnaire (MCQ) (ability of cognitive fusion)<br>-Laboratory parameters: Testosterone, Estrogen, Progesterone, Brain-derived neurotrophic factor (BDNF), Cortisol.<br>- Elektrodermal Activity (EDA) <br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.